Shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) traded down 2.5% on Monday . The stock traded as low as $0.43 and last traded at $0.45. 9,672 shares were traded during trading, a decline of 51% from the average session volume of 19,655 shares. The stock had previously closed at $0.46.
HCW Biologics Price Performance
The company has a 50 day moving average of $0.52 and a two-hundred day moving average of $0.79. The firm has a market cap of $16.98 million, a P/E ratio of -0.59 and a beta of 0.80. The company has a quick ratio of 0.10, a current ratio of 0.10 and a debt-to-equity ratio of 0.95.
HCW Biologics (NASDAQ:HCWB – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter. HCW Biologics had a negative net margin of 978.03% and a negative return on equity of 385.90%. The firm had revenue of $0.62 million for the quarter.
Institutional Investors Weigh In On HCW Biologics
About HCW Biologics
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
Read More
- Five stocks we like better than HCW Biologics
- What does consumer price index measure?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Profitably Trade Stocks at 52-Week Highs
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.